Solborn Swings to Operating Profit of KRW 3.6B in Q1 2026, Transfers KRW 23B from Capital Reserves to Retained Earnings

Consolidated Q1 2026 revenue KRW 35.3B (vs. KRW 24.8B YoY, +42%), operating profit KRW 3.6B (vs. operating loss KRW 6.0B YoY), net profit KRW 8.2B (vs. net loss KRW 9.3B YoY), swinging to black.
Standalone: revenue KRW 305M, operating loss KRW 605M, net loss KRW 823M.
Transferred KRW 23.0B from capital reserves to retained earnings, increasing dividend capacity.
Consolidated debt-to-equity ratio 20.22%, net cash position (cash KRW 16.9B, borrowings KRW 0.6B).
Trade receivables allowance rate 27.41% (long-term loans 60.34%), financial soundness adequate.
Subsidiary Infinitt Healthcare's AI endoscopy diagnostic aid system (INFINITT Smart Endo) designated as a 'evaluation deferred new health technology' in Jan 2026.
Infinitt Healthcare faced tax penalty KRW 1.46B and KOSDAQ listing review in 2025, but listing was maintained in Jan 2026.
Standalone: all treasury shares disposed; consolidated: subsidiary acquired treasury shares worth KRW 0.28B. No share cancellation.